𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Soluble urokinase plasminogen activator receptor as a prognostic marker in men participating in prostate cancer screening

✍ Scribed by A. Kjellman; O. Akre; O. Gustafsson; G. Høyer-Hansen; H. Lilja; U. Norming; T. Piironen; M. Törnblom

Book ID
108863799
Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
167 KB
Volume
269
Category
Article
ISSN
0954-6820

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Urokinase plasminogen activator: A progn
Urokinase plasminogen activator: A prognostic marker in multiple types of cancer
✍ Duffy, Michael J.; Maguire, Teresa M.; McDermott, Enda W.; O'Higgins, Niall 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 143 KB 👁 2 views

Urokinase plasminogen activator (uPA) is a serine protease causally involved in cancer invasion and metastasis. Consistent with its role in cancer spread, uPA has been shown to be a prognostic marker in a variety of malignancies, especially breast cancer. Approximately 20 different groups have shown

The content of urokinase-type plasminoge
The content of urokinase-type plasminogen activator antigen as a prognostic factor in urinary bladder cancer
✍ Yoshihiro Hasui; Kousuke Marutsuka; Junji Suzumiya; Shinichiro Kitada; Yukio Osa 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 French ⚖ 369 KB

## Urokinase -type plasminogen activator (u-PA) is thought to be implicated in cancer invasion and metastasis. The aim of this study was to determine whether the u-PA content of cancer tissue is a prognostic factor in bladder cancer. Tissue samples from 46 patients with bladder cancer were assesse

Soluble urokinase plasminogen activator
Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy
✍ Ove Andersen; Jesper Eugen-Olsen; Kristian Kofoed; Johan Iversen; Steen B. Hauga 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 224 KB

## Abstract Circulating soluble urokinase plasminogen activator receptor (suPAR) reflects the immune and pro‐inflammatory status of the HIV‐infected patient. Highly active antiretroviral therapy (HAART) suppresses suPAR. Independent of the immune response to HAART, suPAR remains elevated in some HI